SCHEMBL5960697

SCHEMBL5960697

CC(=O)NC1=CCCC=C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
HSD17B10 Q99714 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GAA P10253 2/20 0.34
PKM P14618 1/20 0.34
ALOX15 P16050 1/20 0.34
HTT P42858 1/20 0.34
NAPRT Q6XQN6 1/20 0.34
MAPT P10636 3/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 4/20 0.33
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.33
CA12 O43570 1/20 0.33
BRD4 O60885 1/20 0.33
NR1I2 O75469 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6695367 0.81 RXFP1 (0.38) L3MBTL1GAAHTTPOLBKMT2A
SCHEMBL10140100 0.80 ALDH1A1 (0.39) SMN1; SMN2MAPTPOLBKMT2AALDH1A1
SCHEMBL18726609 0.79 GAA (0.34) GAAMAPTKMT2AALDH1A1MEN1
SCHEMBL22048032 0.79 MAPT (0.33) SMN1; SMN2HSD17B10L3MBTL1GAAPKM
SCHEMBL27644272 0.79 L3MBTL1 (0.44) SMN1; SMN2L3MBTL1GAAHTTMAPT
SCHEMBL22019074 0.76 NPC1 (0.38) SMN1; SMN2L3MBTL1GAAHTTMAPT
SCHEMBL22202094 0.76
SCHEMBL23871973 0.76 TP53 (0.43) SMN1; SMN2GAAHTTMAPTPOLB
SCHEMBL20867336 0.75 HDAC1 (0.36) L3MBTL1POLBLMNABRD4NR1I2
SCHEMBL19512667 0.74 NFKB1 (0.40) GAAALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF ASIA VISION LIMITED (CN) 2024-07-18 US disclosed
WO-2023064458-A1 SELECTIVE JAK2 INHIBITORS AND METHODS OF USE YALE UNIVERSITY (US) 2023-04-20 WO disclosed
EP-3596069-B1 KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO SCRIPPS RESEARCH INST (US) 2022-07-13 EP disclosed
EP-2881394-B1 CONDENSED RING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 EP disclosed
EP-1696912-B1 PYRAZOLOPYRIDINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2016-05-11 EP disclosed
US-8901072-B2 Glycopeptide and lipoglycopeptide antibiotics with improved solubility THE MEDICINES COMPANY (US) 2014-12-02 US disclosed
CN-102712649-A Benzimidazole derivatives and pharmaceutical compositions and uses thereof KBP BIOSCIENCES CO LTD 2012-10-03 CN disclosed
US-20060009496-A1 Method for preventing hemoprotein and heme-mediated lipid peroxidation OATES JOHN A 2006-01-12 US disclosed
WO-2006002073-A2 METHOD FOR PREVENTING HEME-INDUCED LIPID PEROXIDATION VANDERBILT UNIVERSITY (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009496-A1 Method for preventing hemoprotein and heme-mediated lipid peroxidation HMOX1, HMOX2, GPX4 SMN1; SMN2 4673/4885HSD17B10 203/4885L3MBTL1 2377/4885
US-20240239792-A1 MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF BCL2, BCL2L2, BCL2L1 SMN1; SMN2 2622/4885HSD17B10 2205/4885L3MBTL1 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.